Evidence map›Paper›PMID 32997295›Full record

SynthesisJournal of neurology2021

Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis.

Qianshuo Lu, Jingjing Luo, Hongjun Hao, Ran Liu, Haiqiang Jin, Yunyi Jin, Feng Gao

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Induction of immune tolerance in NMOSD and MOGAD.Therapeutic advances in neurological disorders · 2025
    Review
  4. Article
  5. MOG Antibody Disease: Nuances in Presentation, Diagnosis, and Management.Current neurology and neuroscience reports · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.International journal of molecular sciences · 2022
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Qianshuo Lu *Department of Neurology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, China, 100034.
Jingjing Luo *Department of Neurology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, China, 100034.
Hongjun HaoDepartment of Neurology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, China, 100034.
Ran LiuDepartment of Neurology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, China, 100034.
Haiqiang JinDepartment of Neurology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, China, 100034.
Yunyi JinDepartment of Neurology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, China, 100034.
Feng GaoDepartment of Neurology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, China, 100034. gaofh2011@163.com.
Peking University First Hospital · CNPeking University · CN

Funding

Peking University Peking University Health Science Center - University of Ulm Joint Center for Neuroscience fund (PKU2017ZC001-1)
6 · The paper itself

Abstract

objectiveTo summarise the evidence of the efficacy and safety of current long-term immunotherapies in patients with myelin oligodendrocyte glycoprotein antibody disease (MOG-AD).

methodsWe performed a sensitive literature search in MEDLINE and EMBASE for selected studies or case series discussing the long-term treatments and outcomes in adult patients with MOG-AD and conducted a qualitative analysis of each therapy.

resultsA total of 33 articles, including 712 patients with MOG-AD, matched our inclusion criteria, and seven kinds of drugs were analysed accordingly. Efficacy was mainly reflected by the change in the annual relapse rate before and after treatment. First, maintenance steroids, azathioprine, mycophenolate mofetil, and rituximab were demonstrated to be effective in multiple studies. However, relapses could still happen after therapy especially under specific circumstances. Second, regular intravenous immunoglobulin G (IVIG) and tocilizumab might be effective. IVIG reduced annual relapse rate and expanded disability status scale in five adult patients, and tocilizumab succeeded in preventing relapse in four refractory patients, though with scant evidence. Finally, multiple sclerosis-disease-modifying therapy seemed ineffective for patients with MOG-AD. As for safety, six patients experienced severe neutropenia during rituximab therapy. No other serious adverse events were reported for these treatments.

conclusionsSeveral preventive immunotherapies have been demonstrated to be effective and safe for adult patients with MOG-AD; however, large controlled studies for subgroups with specific manifestations are still needed in the future.

Indexed as

Immunologic FactorsImmunotherapyAdultAutoantibodiesAzathioprineDemyelinating DiseasesHumansMyelin-Oligodendrocyte GlycoproteinRituximabAutoantibodiesAzathioprineImmunologic FactorsMyelin-Oligodendrocyte GlycoproteinRituximabLong-term immunotherapiesMyelin oligodendrocyte glycoprotein antibody diseaseSystematic reviewTreatment and outcome

Identifiers

PMID32997295
OpenAlexW3089997115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.